Gasim Gasim I, Bella Abdelhaleem, Adam Ishag
Gasim I Gasim, Ishag Adam, Qassim College of Medicine, Qassim University, PO Box 15085 Buraydah, Saudi Arabia.
World J Hepatol. 2015 Feb 27;7(2):270-5. doi: 10.4254/wjh.v7.i2.270.
Infection with hepatitis B virus (HBV) poses a major health threat worldwide, where the magnitude and overburden of chronic carrier state approaches 150 million chronic carriers. The prevalence of HBV is greater among dialyzed patients compared to the general population owing to their increased vulnerability to blood and its products, along with hazards posed by contaminated hemodialysis tools and devices. An electronic systematic search of the published literature was carried and data on the immunological riposte to hepatitis B vaccination among hemodialysis patients was extracted from relevant studies. End stage renal disease patients on hemodialysis have a lower or an absolutely negative riposte to HBV vaccine. Several means have been tried to improve this response with some success, nevertheless none have been universally adopted. Genetic investigations are foreseen to make a break through concerning HBV vaccination.
感染乙型肝炎病毒（HBV）在全球范围内构成重大健康威胁，慢性携带者状态的规模和负担接近1.5亿慢性携带者。与普通人群相比，透析患者中HBV的患病率更高，这是因为他们更容易接触血液及其制品，同时还面临受污染的血液透析工具和设备带来的危害。我们对已发表的文献进行了电子系统检索，并从相关研究中提取了血液透析患者对乙型肝炎疫苗免疫反应的数据。接受血液透析的终末期肾病患者对HBV疫苗的反应较低或完全呈阴性。人们尝试了多种方法来改善这种反应并取得了一些成功，但没有一种方法被普遍采用。预计基因研究将在HBV疫苗接种方面取得突破。
